Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 1/2014

01-03-2014 | Epidemiology and Pathophysiology (PR Ebeling and EF Eriksen, Section Editors)

The Role of Wnt Signaling and Sclerostin in the Pathogenesis of Glucocorticoid-Induced Osteoporosis

Authors: Núria Guañabens, Laia Gifre, Pilar Peris

Published in: Current Osteoporosis Reports | Issue 1/2014

Login to get access

Abstract

Bone formation is suppressed in glucocorticoid-induced osteoporosis. One of the mechanisms by which glucocorticoids depress bone formation is through their effects on the Wnt/β-catenin signaling pathway, a critical regulator of osteoblastogenesis. Thus, Wnt signaling induces the differentiation of osteoblast precursors toward mature osteoblasts and prevents osteoblast and osteocyte apoptosis. Glucocorticoids increase the expression of Wnt signaling antagonists (sclerostin and Dkk-1) in experimental studies in rodents and cell cultures. However, the scarce data of their effects in humans are somewhat contradictory, probably due to the dose and duration of treatment as well as the characteristics of the patients. A progressive decrease in Dkk-1 serum levels and an increase in circulating sclerostin levels at long-term follow-up have recently been reported in patients treated with high doses of glucocorticoids. This review describes the most recent data on the effects of glucocorticoids on the Wnt signaling pathway, especially on their antagonists, sclerostin and Dkk-1.
Literature
1.
Weinstein RS. Glucocorticoid-induced bone disease. In: Rosen CF, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th ed. American Society for Bone and Mineral Research. Iowa, USA: Wiley; 2013. p. 473–81.
2.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319–28.PubMedCrossRef
3.
4.•
Bultink IEM, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013;14:185–97. This article reviews the current concepts on the pathogenesis and management of glucocorticoid-induced osteoporosis.PubMedCrossRef
5.
Bellido T. Antagonistic interplay between mechanical forces and glucocorticoids in bone: a tale of kinases. J Cell Biochem. 2010;111:1–6.PubMedCrossRef
6.
Plotkin LI, Manolagas SC, Bellido T. Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival: evidence for inside-out signaling leading to anoikis. J Biol Chem. 2007;282:24120–30.PubMedCrossRef
7.
Xia X, Kar R, Gluhak-Heinrich J, Yao W, Lane NE, Bonewald LF, et al. Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res. 2010;25:2479–88.PubMedCrossRef
8.
Sambrook PN, Hughes DR, Nelson AE, Robinson BG, Mason RS. Osteocyte viability with glucocorticoid treatment: relation to histomorphometry. Ann Rheum Dis. 2003;62:1215–7.PubMedCrossRef
9.
Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45:2163–72.PubMedCrossRef
10.
Canalis E. Wnt signaling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol. 2013;9:575–83.PubMedCrossRef
11.••
Baron R, Kneissel M. Wnt signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179–92. This article is an extensive review on Wnt signaling in bone homeostasis.PubMedCrossRef
12.
13.
14.
Baron R, Rawadi G. Targeting the Wnt/ß-Catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635–43.PubMedCrossRef
15.
Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39:754–66.PubMedCrossRef
16.
Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009;113:517–25.PubMedCrossRef
17.
Voorzaner-Rousselot N, Goehrig D, Facon T, Clézardin P, Garnero P. Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. Br J Haematol. 2009;145:264–6.CrossRef
18.
Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26:373–9.PubMedCrossRef
19.
Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2010;26:27–34.CrossRef
20.
Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011;26:2812–22.PubMedCrossRef
21.
Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signaling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in postmenopausal women. Bone. 2013;56:42–7.PubMedCrossRef
22.
Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D. Circulating sclerostin and dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012;90:473–80.PubMedCrossRef
23.
Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide. Osteoporos Int. 2012;23:1171–6.PubMedCrossRef
24.
Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013;24:489–94.PubMedCrossRef
25.
Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010;95:2248–53.PubMedCrossRef
26.
Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone. 2012;50:739–42.PubMedCrossRef
27.
Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naïve postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab. 2013;98:3206–12.PubMedCrossRef
28.
Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR, et al. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res. 2012;27:2259–63.PubMedCrossRef
29.
Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ. Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab. 2011;96:E1848–51.PubMedCrossRef
30.
Piemonte S, Romagnoli E, Bratengeier C, Woloszczuk W, Tancredi A, Pepe J, et al. Serum sclerostin levels decline in postmenopausal women with osteoporosis following treatment with intermittent parathyroid hormone. J Endocrinol Invest. 2012;35:866–8.PubMed
31.
Li C, Xing Q, Yu B, Xie H, Wang W, Shi C, et al. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH. J Bone Miner Res. 2013;8:2094–108.CrossRef
32.
Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011;52:44326–35.CrossRef
33.
Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2009;379:261–6.PubMedCrossRef
34.
Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun. 2005;329:177–81.PubMedCrossRef
35.
Butler JS, Queally JM, Devitt BM, Murray DW, Doran PP, O’Byrne JM. Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation. BMC Musculoskelet Disord. 2010;11:210.PubMedCentralPubMedCrossRef
36.
Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H. Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int. 2009;85:538–45.PubMedCrossRef
37.
Hurson CJ, Butler JS, Keating DT, Murray DW, Sadlier DM, O’Byrne JM, et al. Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis. BMC Musculoskelet Disord. 2007;8:12.PubMedCentralPubMedCrossRef
38.
Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2004;318:259–64.PubMedCrossRef
39.
Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008;58:1674–86.PubMedCentralPubMedCrossRef
40.
Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL. Modulation of dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology. 2008;149:1793–801. PubMedCrossRef
41.••
Thiele S, Ziegler N, Tsourdi E, De Bosscher K, Tuckermann JP, Hofbauer LC, et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res. 2012;27:2242–50. This article assesses the effect of glucocorticoid treatment in cultures of osteoblasts and osteocytes, as well as in rodents.PubMedCrossRef
42.
Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum. 2011;63:2385–95.PubMedCrossRef
43.••
Brabnikova Maresova K, Pavelka K, Stepan JJ. Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. Calcif Tissue Int. 2013;92:354–61. This article assesses the levels of sclerostin and Dkk-1 in patients with glucocorticoid treatment at short term.PubMedCrossRef
44.•
Gifre L, Ruiz-Gaspà S, Monegal A, Nomdedeu B, Filella X, Guañabens N, et al. Effect of glucocorticoid treatment on Wnt signaling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone. 2013;57:272–6. This article assesses the levels of sclerostin and Dkk-1 in patients with glucocorticoid treatment at short and long term.PubMedCrossRef
45.•
Gossiel F, Lane N, Eastell R. The effect of glucocorticoid therapy on regulators of bone formation in postmenopausal women treated with teriparatide or alendronate. ASBMR Annual Meeting; 2011. p. S80 [Abstract]. This abstract assesses the levels of sclerostin and Dkk-1 in patients with glucocorticoid treatment in the short-term.
46.
Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV, et al. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing’s syndrome. Osteoporos Int. 2013;24:2191–9.PubMedCrossRef
47.
van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE. Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab. 2012;97:E1953–7.PubMedCrossRef
48.
Morse LR, Sudhakar S, Danilack V, Tun C, Lazzari A, Gagnon DR, et al. Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res. 2012;27:352–9.PubMedCentralPubMedCrossRef
49.
Brunetti G, Faienza MF, Piacente L, Ventura A, Oranger A, Carbone C, et al. High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. Am J Physiol Endocrinol Metab. 2013;304:E546–54.PubMedCrossRef
Metadata
Title
The Role of Wnt Signaling and Sclerostin in the Pathogenesis of Glucocorticoid-Induced Osteoporosis
Authors
Núria Guañabens
Laia Gifre
Pilar Peris
Publication date
01-03-2014
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 1/2014
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-014-0197-0

Other articles of this Issue 1/2014

Current Osteoporosis Reports 1/2014 Go to the issue

Epidemiology and Pathophysiology (PR Ebeling and EF Eriksen, Section Editors)

Review: Epidemiology and Pathophysiology of Atypical Femur Fractures

Skeletal Biology and Regulation (MR Forwood and A Robling, Section Editors)

Regulatory Mechanisms of RANKL Presentation to Osteoclast Precursors

Epidemiology and Pathophysiology (PR Ebeling and EF Eriksen, Section Editors)

Vitamin D Deficiency and its Role in Muscle-Bone Interactions in the Elderly

Epidemiology and Pathophysiology (PR Ebeling and EF Eriksen, Section Editors)

Bone Metabolism in Anorexia Nervosa

Regenerative Biology and Medicine in Osteoporosis (EM Schwartz and RE Guldberg, Section Editors)

Local Strategies to Prevent and Treat Osteoporosis

Osteoimmunology (D Novack and G Schett, Section Editors)

Mesenchymal Progenitors and the Osteoblast Lineage in Bone Marrow Hematopoietic Niches